The prevalence of IDH1 mutations varies across cancer types. For instance, studies report that approximately 70-80% of low-grade gliomas and secondary glioblastomas harbor IDH1 mutations. In contrast, IDH1 mutations are found in around 10-20% of AML cases. The frequency of these mutations can be influenced by factors such as age, sex, and environmental exposures.
